Quick Summary: Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue and the only peptide in its class with FDA approval — granted in 2010 for HIV-associated lipodystrophy. Phase 3 randomised controlled trials document visceral fat reductions of approximately 15–18% over 26 weeks. This guide covers the full evidence base: mechanism, clinical data, safety profile, administration protocols, emerging research, and UK sourcing context.
What Is Tesamorelin?
Tesamorelin (brand name Egrifta; Egrifta SV) is a stabilised full-sequence analogue of endogenous human growth hormone-releasing hormone (GHRH). It was developed by Theratechnologies and received U.S. Food and Drug Administration approval in November 2010 — making it the first and only GHRH analogue with regulatory approval for an adult metabolic indication. The approved indication is the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, a condition characterised by pathological visceral fat accumulation caused by antiretroviral therapy.
Within the landscape of peptide research, tesamorelin occupies a unique position: it is not merely an investigational compound but one with a Phase 3 evidence base, a known pharmacological mechanism, characterised safety data, and decades of clinical use in its approved indication. This makes it one of the most scientifically grounded GHRH analogues available for research study.
Tesamorelin Mechanism of Action
GHRH Receptor Agonism and Pulsatile GH Release
Tesamorelin’s mechanism begins with selective binding to GHRH receptors on somatotroph cells in the anterior pituitary gland. Endogenous GHRH — a 44-amino acid hypothalamic peptide — is degraded within minutes in plasma by dipeptidyl peptidase-4 (DPP-4). Tesamorelin addresses this through the addition of a trans-2-hexadecenoic acid moiety to the N-terminus of the full GHRH sequence, conferring resistance to enzymatic cleavage while preserving receptor binding specificity and biological activity.
The result is stimulation of pulsatile growth hormone (GH) secretion that closely mirrors the body’s natural physiological pattern. This mechanistic distinction is clinically significant: unlike exogenous recombinant human GH (rhGH) administration, which delivers GH directly and bypasses the hypothalamic-pituitary feedback axis, tesamorelin works through the natural regulatory architecture. Somatostatin — the endogenous GH-suppressing hormone — retains its inhibitory function, preventing runaway GH elevation and moderating the ceiling of stimulation.
Downstream IGF-1 Elevation
Once GH is secreted in response to tesamorelin stimulation, it travels to the liver and stimulates production of insulin-like growth factor-1 (IGF-1), the primary mediator of GH’s metabolic and anabolic effects. In clinical trials, once-daily tesamorelin administration raised mean IGF-1 SD scores by approximately 1.0–1.5 SD above baseline by week 26 — generally within or slightly above the age-adjusted normal physiological range. This IGF-1 elevation is considered the primary pharmacodynamic marker of on-target activity and is used to guide monitoring protocols in clinical and research settings.
Preferential Visceral Fat Lipolysis
The selectivity of tesamorelin’s fat-reducing effects for visceral adipose tissue (VAT) over subcutaneous fat is one of its defining pharmacological features. Visceral adipocytes express a higher density of GH receptors than subcutaneous fat cells and are more metabolically responsive to GH-stimulated lipolysis. When tesamorelin restores pulsatile GH release in individuals with relative GH deficiency, the lipolytic stimulus preferentially mobilises triglycerides from visceral depots — releasing free fatty acids for oxidation — while subcutaneous fat is comparatively unaffected. This selectivity is pharmacologically coherent and has been consistently demonstrated across Phase 3 trial CT imaging data.
Clinical Evidence: Phase 3 Trials
The LIPO-010 and LIPO-011 Trials
The foundational clinical evidence for tesamorelin comes from two pivotal Phase 3 randomised placebo-controlled trials — LIPO-010 and LIPO-011 — which enrolled a combined total of over 800 HIV-positive adults with antiretroviral-related lipodystrophy. The primary endpoint in both trials was change in visceral adipose tissue area measured by cross-sectional computed tomography (CT) at the umbilical level, assessed at 26 weeks. Both trials met their primary endpoints with high statistical significance.
Across the pooled Phase 3 data, tesamorelin-treated participants achieved mean VAT reductions of approximately 49 cm² — representing a 15–18% reduction from baseline visceral fat volume — compared with a modest increase in the placebo group. Waist circumference reductions of 2–4 cm were documented as a secondary endpoint. Patient-reported improvements in trunk appearance and body image satisfaction were statistically significant in the tesamorelin group, reflecting the psychosocial dimension of visceral fat reduction in a population where lipodystrophy carries substantial stigma.
52-Week Extension Data and VAT Maintenance
Participants who completed the initial 26-week treatment period were eligible for an extension phase examining outcomes through 52 weeks. Those who continued active tesamorelin maintained the VAT reductions achieved at 26 weeks throughout the extension period, without evidence of progressive fat loss or accumulating safety signals. Crucially, participants re-randomised to placebo after the initial 26-week active phase showed progressive visceral fat regain — with approximately 50–80% of the reduction reversed within 26 weeks of switching to placebo. This discontinuation-and-rebound pattern confirms that tesamorelin’s effects are pharmacologically maintained rather than sustained after cessation.
Secondary Metabolic Endpoints
Beyond visceral fat area, the Phase 3 trials documented several secondary metabolic improvements in the tesamorelin group: statistically significant reductions in fasting triglycerides (mean decreases of 15–25 mg/dL), improvements in waist-to-hip ratio, and favourable trends in carotid intima-media thickness (CIMT) — a surrogate marker of subclinical atherosclerosis — in extended analyses (Fitch et al., Circulation: Cardiovascular Imaging, 2017). Lean mass changes were modest and non-significant in most analyses, but directionally favourable — consistent with GH’s anabolic effects on protein synthesis and lean tissue preservation.
Tesamorelin for Non-HIV Metabolic Syndrome
A pilot randomised controlled study by Falutz et al. published in the Journal of Clinical Endocrinology & Metabolism examined tesamorelin in adults with metabolic syndrome who did not have HIV infection. The study found significant VAT reductions, trunk fat improvements, and lipid profile changes compared with placebo at 26 weeks — consistent in magnitude with the HIV-lipodystrophy trial data. While the sample size was insufficient for definitive conclusions, these findings support the mechanistic generalisation that tesamorelin’s visceral fat-reducing action is not exclusive to the HIV context but reflects a broader effect on GH-axis-regulated adipose biology.
Administration: Protocols from Clinical Research
Once-Daily Subcutaneous Injection
Every major published clinical trial studying tesamorelin has used a once-daily subcutaneous injection protocol. This frequency is dictated by the compound’s pharmacokinetics: despite its structural modifications that improve DPP-4 resistance compared to native GHRH, tesamorelin’s plasma half-life is still measured in minutes-to-hours rather than days. Maintaining the GH pulsatility necessary to sustain downstream IGF-1 elevation and the associated metabolic effects requires daily pituitary stimulation. Subcutaneous delivery provides predictable absorption and avoids first-pass hepatic metabolism.
Treatment Duration: 26 to 52 Weeks
The primary efficacy window in the pivotal trials was 26 weeks, at which point CT-measured VAT reductions were statistically significant and clinically meaningful. Extension data through 52 weeks showed maintenance of the 26-week reductions without evidence of diminishing returns or progressive accumulation of safety signals in the majority of participants. Long-term extension studies have followed cohorts for up to two years, which represents the outer bound of the available continuous-use data in any well-controlled cohort. Beyond two years, published safety evidence is limited.
IGF-1 as a Pharmacodynamic Marker and Monitoring Tool
In all trial protocols, serum IGF-1 was measured at regular intervals as the primary pharmacodynamic marker of on-target biological activity. IGF-1 normalisation toward age-adjusted reference ranges confirms that the pituitary is responding to tesamorelin stimulation. In clinical protocols, IGF-1 values substantially above the upper limit of the age-adjusted normal range trigger reassessment of continued use, as supraphysiological IGF-1 elevation is associated with insulin resistance and carries a theoretical cancer risk signal that warrants caution.
Safety Profile
FDA Approval and Regulatory Safety Assessment
Tesamorelin’s FDA approval in 2010 followed a comprehensive regulatory review of the Phase 3 trial safety data. The approved prescribing information for Egrifta/Egrifta SV provides the most authoritative characterisation of the compound’s safety profile, incorporating data from all Phase 2 and Phase 3 trials. This regulatory imprimatur distinguishes tesamorelin from investigational peptides with limited safety documentation and provides a well-characterised baseline from which emerging research populations can be compared.
Common Adverse Events
The most frequently reported adverse events across Phase 3 trials were injection-site reactions (erythema, pruritus, pain, urticaria at the subcutaneous administration site), peripheral oedema (fluid retention consistent with GH-related sodium and water retention effects), arthralgia (joint pain), myalgia, and paraesthesia. These effects reflect the pharmacological consequences of GH axis activation and are consistent with what is observed in growth hormone replacement therapy more broadly. The majority were mild-to-moderate in severity and did not result in treatment discontinuation.
Carpal tunnel syndrome — caused by GH-related fluid accumulation in the wrist canal — was observed at low but non-trivial rates in treated participants, consistent with GH excess states such as acromegaly. Its clinical significance increases with duration of exposure.
Glucose Metabolism: The Most Clinically Significant Safety Signal
Growth hormone’s counter-regulatory effects on insulin signalling are well established, and tesamorelin’s glucose metabolism signal is the most clinically significant safety consideration in the published literature. Phase 3 trial data showed modest but statistically significant increases in fasting glucose and insulin resistance markers in tesamorelin-treated participants compared with placebo. Participants with pre-existing glucose dysregulation showed the greatest metabolic perturbation. The prescribing information includes a warning regarding glucose intolerance and diabetes, with monitoring of blood glucose throughout treatment specified as standard practice.
Importantly, glucose-raising effects were largely reversible on discontinuation — fasting glucose and insulin resistance markers returned toward baseline within weeks of stopping treatment in the majority of participants. However, in metabolically vulnerable individuals, the acceleration of glucose dysregulation during a treatment period represents a real clinical risk that must be weighed in the benefit-risk calculation.
IGF-1 Elevation and the Theoretical Cancer Risk
Because tesamorelin reliably raises IGF-1 — a mitogenic growth factor associated in epidemiological studies with elevated risk of certain cancers — the question of whether sustained IGF-1 elevation translates to clinically meaningful cancer risk is one of the most scrutinised aspects of its long-term safety profile. The Phase 3 trials did not identify a statistically significant increase in cancer incidence in treated participants. However, trial follow-up periods of one to two years are insufficient to detect carcinogenic effects, which typically manifest over decades. Tesamorelin is contraindicated in active malignancy across all regulatory jurisdictions, consistent with the precautionary approach applied to all GH-axis-stimulating compounds in oncology contexts.
Absolute Contraindications
The regulatory literature identifies three absolute contraindications: active malignancy (given mitogenic IGF-1 properties), pituitary pathology including pituitary tumours or prior pituitary irradiation (which alter pituitary responsiveness to GHRH stimulation unpredictably), and pregnancy (due to potential IGF-1-mediated growth factor effects on foetal development). These contraindications are consistent across FDA, EMA, and Health Canada regulatory documentation.
The Two-Year Evidence Ceiling
A foundational limitation of the tesamorelin safety literature is the two-year ceiling on well-controlled continuous-use data. The questions that matter most from a long-term safety standpoint — cancer incidence over a decade of use, cumulative cardiovascular effects, and sustained neuroendocrine consequences — cannot be definitively answered by the available evidence. This is not unique to tesamorelin but reflects the inherent limitations of pre-approval clinical trial designs. The most scientifically defensible characterisation of tesamorelin’s long-term profile is that it is incompletely understood beyond two years, with documented short-term risks that are manageable with appropriate monitoring and are largely reversible on discontinuation.
Emerging Research Areas
Cognitive Function and Brain Health
An intriguing body of research has examined tesamorelin’s effects on cognitive function in older adults, motivated by the known roles of GH and IGF-1 in neuroplasticity, synaptic function, and amyloid beta clearance. GH receptors are present in the hippocampus and prefrontal cortex — brain regions critical for memory and executive function — and age-related GH decline (somatopause) has been linked epidemiologically to increased cognitive impairment risk.
A Phase 2 randomised controlled trial by Baker et al. (published in JAMA Neurology) investigated once-daily tesamorelin over 20 weeks in cognitively normal older adults and individuals with mild cognitive impairment (MCI). The study found statistically significant improvements in verbal memory and executive function in the tesamorelin group compared with placebo, with effects persisting at a post-washout follow-up assessment. A subsequent longer-duration trial found favourable changes in cerebrospinal fluid biomarkers of Alzheimer’s pathology alongside slower cognitive decline in treated participants. These findings are preliminary and require replication in larger trials, but represent one of the most compelling emerging signals in the tesamorelin research literature.
Non-Alcoholic Fatty Liver Disease (NAFLD/NASH)
Tesamorelin’s visceral fat-reducing and GH-axis-restoring properties have motivated investigation into its role in managing non-alcoholic fatty liver disease (NAFLD) — now reclassified as metabolic-associated steatotic liver disease (MASLD). Adult GH deficiency is associated with elevated rates of hepatic steatosis, and restoring GH pulsatility through tesamorelin may reverse hepatic fat accumulation through mechanisms parallel to those observed in the HIV-lipodystrophy setting.
A randomised controlled trial by Stanley et al. published in Gastroenterology (2020) examined once-daily tesamorelin over 12 months in adults with HIV and NASH confirmed on liver biopsy. Participants receiving tesamorelin showed significant reductions in hepatic fat fraction by MRI-PDFF and favourable histological changes including reductions in steatosis grade. These findings position tesamorelin as a potentially meaningful intervention in hepatic fat management, though larger non-HIV trials are required before the liver disease signal can be considered definitive.
Age-Related Somatopause and Central Adiposity
Beyond specific disease states, researchers have investigated whether tesamorelin’s ability to restore GH pulsatility could attenuate the age-related central adiposity that characterises normal somatopause. GH secretion declines at approximately 14% per decade after early adulthood, and this progressive deficit underlies much of the body composition shift — increasing visceral fat, decreasing lean mass — that occurs with normal ageing. Studies in healthy older adults have demonstrated that GHRH-based interventions can meaningfully amplify GH pulsatility in elderly populations, restoring IGF-1 toward younger physiological ranges. Whether these hormonal changes translate into clinically significant and durable reductions in visceral fat in non-pathologically deficient elderly individuals requires larger, longer trials to determine.
Tesamorelin vs Other GHRH Analogues
Tesamorelin vs Sermorelin
Sermorelin is an older GHRH analogue comprising the first 29 amino acids of endogenous GHRH — sufficient for GHRH receptor binding and activation. It was the first GHRH analogue to receive FDA approval (for paediatric GH deficiency, 1997), though it was subsequently withdrawn from the U.S. market for commercial rather than safety reasons. Structurally, sermorelin differs from tesamorelin in that it lacks the full 44-amino acid sequence and the stabilising fatty acid modification. Tesamorelin’s greater receptor binding affinity and longer functional duration in plasma give it a more potent and sustained effect compared with sermorelin at equivalent doses. The clinical evidence base for tesamorelin in adult metabolic indications substantially exceeds that for sermorelin, which has been studied primarily in smaller Phase 2 trials in older adult and anti-ageing medicine contexts.
Tesamorelin vs CJC-1295
CJC-1295 is a GHRH analogue incorporating drug affinity complex (DAC) technology that enables albumin binding, extending its half-life to approximately 6–8 days and permitting once- or twice-weekly dosing rather than the once-daily schedule required by tesamorelin. This pharmacokinetic difference arises from a fundamental structural design choice: CJC-1295’s albumin-binding technology dramatically extends its circulating duration. However, CJC-1295 remains a research compound with no FDA-approved indication and a substantially more limited published clinical dataset than tesamorelin. No Phase 3 randomised controlled trials with meaningful clinical endpoints (body composition, metabolic markers, cognitive function) have been published for CJC-1295. From an evidence quality standpoint, tesamorelin holds a substantially stronger position in the scientific literature.
What Happens When Tesamorelin Is Stopped?
The reversibility of tesamorelin’s effects is one of its most pharmacologically important characteristics. When treatment is discontinued, the pituitary-stimulating effect ceases within hours, and GH secretion returns to pre-treatment baseline patterns within days. IGF-1 levels normalise to pre-treatment concentrations within a few weeks. The adverse metabolic effects — glucose elevation, fluid retention, blood pressure changes — also resolve relatively promptly, consistent with the reversible mechanism of GHRH receptor agonism.
For the primary clinical endpoint — visceral fat reduction — the picture is less favourable. Extension trial data show that approximately 50–80% of the VAT reduction achieved during active treatment reverses within 26 weeks of discontinuation, as GH-mediated lipolytic activity ceases and visceral adipocytes resume their preferential fat-storage behaviour. This reversal pattern means that tesamorelin functions as a maintenance therapy rather than a cure: it manages the ongoing pathophysiology driving visceral fat accumulation as long as treatment continues but does not permanently alter the underlying metabolic set point. This characteristic is shared with other hormonal therapies in conditions of chronic deficiency.
Tesamorelin in the UK: Research and Regulatory Context
Tesamorelin does not hold a Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for any indication. The FDA approval under the Egrifta brand name is a U.S. regulatory designation only. In the United Kingdom, tesamorelin is available as a research peptide, and its purchase and use falls within the regulatory framework governing research chemicals and peptide compounds. Researchers and organisations working with tesamorelin in the UK should ensure compliance with current MHRA guidance and consult the applicable regulations governing research peptide handling, storage, and use.
Tesamorelin is available for research purchase at Peptides Lab UK, where it is supplied for laboratory and scientific research purposes only. All products are subject to quality verification and are sold strictly for non-clinical research use in accordance with applicable UK regulations.
Key Research Findings: Summary Table
Primary Indication: HIV-associated lipodystrophy (FDA-approved 2010)
Mechanism: GHRH receptor agonist → pulsatile GH release → IGF-1 elevation → visceral lipolysis
VAT Reduction (Phase 3): ~49 cm² / 15–18% reduction from baseline at 26 weeks
Administration: Once-daily subcutaneous injection
Trial Duration: 26–52 weeks (up to 2 years in extension cohorts)
IGF-1 Change: +1.0–1.5 SD score above baseline; typically within age-adjusted normal range
Key Safety Signal: Modest fasting glucose/insulin resistance elevation; reversible on discontinuation
Contraindications: Active malignancy; pituitary pathology; pregnancy
Reversibility on Cessation: 50–80% of VAT reduction reversed within 26 weeks
Evidence Ceiling: ~2 years continuous use in controlled cohorts
Frequently Asked Questions
What is tesamorelin used for in clinical research?
Tesamorelin is FDA-approved for reducing excess visceral abdominal fat in HIV-infected adults with lipodystrophy. Active research areas include cognitive function in older adults with mild cognitive impairment, non-alcoholic fatty liver disease, metabolic syndrome in non-HIV populations, and age-related somatopause.
How does tesamorelin differ from growth hormone injections?
Tesamorelin stimulates the pituitary to produce and release the body’s own growth hormone in a pulsatile, physiologically regulated pattern. It does not deliver exogenous GH directly. This preserves somatostatin feedback inhibition, moderating the ceiling of GH elevation and reducing the risk of the supraphysiological GH spikes associated with direct GH administration.
How much visceral fat does tesamorelin reduce?
Phase 3 trials in HIV-lipodystrophy populations documented mean visceral adipose tissue area reductions of approximately 49 cm² — representing 15–18% of baseline VAT volume — at 26 weeks. Waist circumference reductions of 2–4 cm were documented as a secondary endpoint. Effects are maintained with continued treatment and largely reverse within 26 weeks of discontinuation.
What are the main side effects of tesamorelin?
The most commonly documented adverse events in Phase 3 trials were injection-site reactions (erythema, pruritus, pain), peripheral oedema, arthralgia, myalgia, and paraesthesia — all consistent with GH axis activation. The most clinically significant concern is modest elevation of fasting glucose and insulin resistance, particularly in individuals with pre-existing metabolic vulnerability. These effects are largely reversible on discontinuation.
Is tesamorelin safe for long-term use?
Clinical trial data extend to approximately two years. Within this window, the safety profile is well-characterised and manageable with appropriate monitoring. Beyond two years, definitive long-term safety data is limited. The most important ongoing concerns are glucose dysregulation (particularly in metabolically vulnerable individuals), the theoretical cancer risk from sustained IGF-1 elevation, and the evidence ceiling that prevents definitive conclusions about decade-long exposure.
Does tesamorelin affect cognitive function?
Emerging clinical trial data (Baker et al., JAMA Neurology) found improvements in verbal memory and executive function in older adults with mild cognitive impairment over 20 weeks of once-daily tesamorelin. These findings are preliminary and require larger confirmatory trials. The biological rationale — GH and IGF-1 receptors in hippocampus and prefrontal cortex, roles in neuroplasticity and amyloid clearance — is well-supported mechanistically.
How does tesamorelin compare to GLP-1 receptor agonists for visceral fat?
GLP-1 receptor agonists (semaglutide, tirzepatide) produce substantial total body weight loss including both visceral and subcutaneous fat, primarily through appetite suppression. Tesamorelin does not suppress appetite or produce generalised weight loss; it acts selectively on the GH axis to preferentially reduce visceral fat without significant changes to subcutaneous fat or total body weight. These mechanistically distinct approaches serve different clinical populations and research questions.
Can tesamorelin be used in UK research?
Tesamorelin is available as a research peptide in the UK. It does not hold MHRA or EMA marketing authorisation. Researchers should ensure compliance with current UK regulations governing research chemical use. Peptides Lab UK supplies tesamorelin for laboratory and scientific research purposes, subject to applicable UK regulatory requirements.
References and Key Literature
Falutz J, et al. Effects of Tesamorelin, a Growth Hormone-Releasing Factor, in HIV-Infected Patients with Abdominal Fat Accumulation. N Engl J Med. 2007;357(23):2349–2359.
Falutz J, et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. N Engl J Med. 2010;363(23):2249–2250.
Stanley TL, et al. Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients with Abdominal Fat Accumulation. JAMA. 2012;307(15):1625–1633.
Grunfeld C, et al. Tesamorelin Suppresses Excess Visceral Adipose Tissue in HIV-Infected Patients. J Acquir Immune Defic Syndr. 2010;53(3):311–322.
Dhillon S. Tesamorelin: A Review of its Use in the Management of HIV-Associated Lipodystrophy. Drugs. 2011;71(8):1071–1091.
Fitch KV, et al. Effects of Tesamorelin on Carotid Intima-Media Thickness in HIV-Infected Adults. Circulation: Cardiovascular Imaging. 2017;10(10):e006574.
Stanley TL, et al. Effect of Tesamorelin on Non-Alcoholic Fatty Liver Disease in HIV. Gastroenterology. 2020;158(4):1044–1052.
Baker LD, et al. Effects of Growth Hormone-Releasing Hormone on Cognitive Function in Adults with Mild Cognitive Impairment and Healthy Older Adults. JAMA Neurology. 2012;69(11):1420–1429.
Falutz J, et al. Long-Term Safety and Effects of Tesamorelin on Glucose Metabolism in HIV-Associated Lipodystrophy. HIV Medicine. 2014;15(10):621–629.
US Food and Drug Administration. EGRIFTA (Tesamorelin for Injection): Prescribing Information. NDA 022505. November 2010; updated 2019.
Disclaimer: This guide is intended for informational and educational purposes only. All content is drawn from peer-reviewed clinical research and published regulatory documentation. Nothing in this guide constitutes medical advice, a treatment recommendation, or guidance for personal use of any kind. Tesamorelin is supplied by Peptides Lab UK strictly for laboratory and scientific research purposes in accordance with applicable UK regulations.
